Pyrazolo[1,5-a][1,3,5]triazine Derivatives for Selective CDK7 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with selective transcriptional cyclin-dependent kinases (CDKs), such as CDK7, CDK9, CDK12, CDK13, and CDK18, lack effective compounds and therapies, with existing inhibitors like flavopiridol having poor toxicity profiles and limited specificity.
Innovation Solution
Development of pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as selective transcriptional CDK inhibitors, which are formulated into pharmaceutical compositions for targeted treatment of diseases related to these CDKs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing CDK inhibitors like flavopiridol are used, then CDK inhibition activity is achieved, but toxicity is high and specificity is poor
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular features tailored to bind selectively to transcriptional CDKs. The compounds contain specific heterocyclic core structures (pyrazolo[1,5-a][1,3,5]triazine or pyrazolo[1,5-a]pyrimidine) with defined substituent patterns that create localized interaction zones for selective binding to the ATP-binding pocket of transcriptional CDKs, thereby achieving high specificity and reduced off-target toxicity.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters such as substituent types (R1-R6), linker structures (L1, L2), and ring configurations to optimize the balance between potency and selectivity. By adjusting these chemical parameters, the invention achieves compounds with improved therapeutic indices that maintain CDK inhibition activity while reducing toxicity through enhanced specificity.
2Reliability
If existing CDK inhibitors like flavopiridol are used, then CDK inhibition activity is achieved, but specificity is poor
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular features tailored to bind selectively to transcriptional CDKs. The compounds contain specific heterocyclic core structures (pyrazolo[1,5-a][1,3,5]triazine or pyrazolo[1,5-a]pyrimidine) with defined substituent patterns that create localized interaction zones for selective binding to the ATP-binding pocket of transcriptional CDKs, thereby achieving high specificity and reduced off-target toxicity.
Solution Approach 2:
The patent uses the ATP-binding pocket of transcriptional CDKs as an intermediary target. The inhibitors are designed to specifically interact with this conserved region through unique molecular features, acting as a mediator that distinguishes transcriptional CDKs from other CDK family members. This intermediary targeting approach enables selective inhibition with high specificity.
3Measurement precision
If selective transcriptional CDK inhibitors are developed, then specificity and toxicity profile are improved, but compound development complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional modules: a core heterocyclic structure (pyrazolo[1,5-a][1,3,5]triazine or pyrazolo[1,5-a]pyrimidine), linker regions (L1, L2), and terminal substituents (R1-R6). This modular segmentation allows systematic optimization of each component for selectivity while simplifying the overall development process through structure-activity relationship analysis.
Solution Approach 2:
The patent employs universality by designing a platform of compounds with a common core structure that can target multiple transcriptional CDKs (CDK7, CDK9, CDK12, CDK13, CDK18). The modular substituent patterns allow the same core scaffold to be adapted for different specificities, reducing development complexity through reusable structural motifs while maintaining high specificity.
Data Source
Figure 1
AI summary
The present invention provides substituted pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives of formula (I), which are therapeutically useful, particularly as selective transcriptional CDK inhibitors including CDK7, CDK9, CDK12, CDK13 and CDK18, more particularly transcriptional CDK7 inhibitors wherein X, ring A, ring B, L1, L2, R1,R2, R3, R4, R6, m, n and p have the meanings given in the specification and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorder associated with selective transcriptional CDKs in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives of formula (I) or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.